Ask an Expert

Question of the Day

Bryan Roth, M.D., Ph.D.
September 16, 2011

There are several novel medications in both early- and later-stage clinical development which hold out hope for new treatment options as well as many in earlier stages of the pipeline. If only one of these proved effective (for example Gly-T I inhibitors currently in Phase III trials), we could expect new options within a couple of years. The early stage medications, coming mainly from pharmaceutical companies, are at least 5 years away. A new pan-NIH-initiative to accelerate drug discovery via academic labs could yield fruit, with a fair amount of luck, within the 5-year timeline.

Bryan L. Roth, M.D., Ph.D.
Scientific Council Member
Michael Hooker Distinguished Professor
Director, NIMH Psychoactive Drug Screening Program
University of North Carolina Chapel Hill Medical School

Eric R. Kandel, M.D. - Brain and behavior research expert on PTSD
Q There is a lot of talk about how to improve memory, but what about erasing traumatic memories from the brains of people that have post-traumatic stress disorder (PTSD)? Is this possible, and if so, do you recommend it?
A I do not like the idea of erasing memories. I think we can provide someone... More >
Karl Deisseroth, M.D., Ph.D. - Brain and behavior research expert on schizophrenia
Q Can you envision ways in which the optogenetics technology that you invented might eventually improve the design or use of psychiatric medications?
A The major challenge we face in psychiatry is understanding. Psychiatric... More >